Comments
yourfanat wrote: I am using another tool for Oracle developers - dbForge Studio for Oracle. This IDE has lots of usefull features, among them: oracle designer, code competion and formatter, query builder, debugger, profiler, erxport/import, reports and many others. The latest version supports Oracle 12C. More information here.
Cloud Expo on Google News
SYS-CON.TV

2008 West
DIAMOND SPONSOR:
Data Direct
SOA, WOA and Cloud Computing: The New Frontier for Data Services
PLATINUM SPONSORS:
Red Hat
The Opening of Virtualization
GOLD SPONSORS:
Appsense
User Environment Management – The Third Layer of the Desktop
Cordys
Cloud Computing for Business Agility
EMC
CMIS: A Multi-Vendor Proposal for a Service-Based Content Management Interoperability Standard
Freedom OSS
Practical SOA” Max Yankelevich
Intel
Architecting an Enterprise Service Router (ESR) – A Cost-Effective Way to Scale SOA Across the Enterprise
Sensedia
Return on Assests: Bringing Visibility to your SOA Strategy
Symantec
Managing Hybrid Endpoint Environments
VMWare
Game-Changing Technology for Enterprise Clouds and Applications
Click For 2008 West
Event Webcasts

2008 West
PLATINUM SPONSORS:
Appcelerator
Get ‘Rich’ Quick: Rapid Prototyping for RIA with ZERO Server Code
Keynote Systems
Designing for and Managing Performance in the New Frontier of Rich Internet Applications
GOLD SPONSORS:
ICEsoft
How Can AJAX Improve Homeland Security?
Isomorphic
Beyond Widgets: What a RIA Platform Should Offer
Oracle
REAs: Rich Enterprise Applications
Click For 2008 Event Webcasts
YM BioSciences Reports Operational and Financial Results for the First Quarter of Fiscal 2013

MISSISSAUGA, ON, Nov. 9, 2012 /PRNewswire/ - YM BioSciences Inc. (NYSE MKT: YMI, TSX: YM), a drug development company advancing hematology and cancer related products, today reported operational and financial results for the first quarter of fiscal 2013, ended September 30, 2012.

"During the quarter we prepared for pivotal trials with CYT387 while continuing to explore potential opportunities to further develop and/or commercialize our drug with other companies," said Dr. Nick Glover, President and CEO of YM BioSciences. "We look forward to reporting final results from the 166 patient Phase I/II study of CYT387 in myelofibrosis, which have been selected for presentation in an Oral Session at the 2012 Annual Meeting of the American Society of Hematology."

Summary Financial Results (CDN dollars)
The interim consolidated financial statements and comparative information for fiscal 2013 have been prepared in accordance with International Financial Reporting Standards ("IFRS").

Revenue, generated from out-licensing remained constant for the first quarter of fiscal 2013 ending September 30, 2012 at $0.3 million compared with $0.3 million for the first quarter of fiscal 2012 ending September 30, 2011.

Net finance income was $0.4 million for the first quarter of fiscal 2013 compared to net finance income of $7.5 million for the first quarter of fiscal 2012. The changes in net finance income are primarily attributable to changes in the fair value adjustment for USD warrants. Under IFRS, warrants denominated in a different currency than the Company's functional currency must be classified as a financial liability and measured at fair value, with changes reflected in profit or loss. For the first quarter of fiscal 2013, the Company realized a gain of $1.7 million on the revaluation of warrants, compared to a gain of $5.4 million for the first quarter of fiscal 2012.

Licensing and product development expenses were $7.2 million for the first quarter of fiscal 2013 compared with $6.5 million for the first quarter of fiscal 2012. Development expenses for CYT387 increased due to preparations for the Phase III program in myelofibrosis, the extension of the Phase I/II clinical trial in myelofibrosis, ongoing costs associated with the BID study, pre-clinical development activities, and manufacturing of drug for these programs.

General and administrative expenses were $2.0 million for the first quarter of fiscal 2013 compared to $2.2 million for the first quarter of fiscal 2012, primarily due to lower non-cash share-based compensation expense.

Net loss for the first quarter of fiscal 2013 was $8.5 million ($0.05 per share) compared to $0.9 million ($0.01 per share) for the same period last year.

As at September 30, 2012 the Company had cash and short-term deposits totaling $125.5 million and accounts payable and accrued liabilities totaling $5.0 million compared to $132.5 million and $3.1 million respectively as at June 30, 2012.

As at September 30, 2012 the Company had 157,546,793 common shares and 7,366,418 warrants outstanding.

Notice of Meeting:
YM's Annual Meeting of Shareholders will be held on November 20, 2012, at 4:00 p.m. ET at the offices of Norton Rose Canada LLP, Boardrooms A & B, 38th Floor, 200 Bay Street, Royal Bank Plaza South Tower, Toronto, Ontario. The management proxy circular documents and annual financial documents were mailed to shareholders on October 8, 2012, and are available online at www.ymbiosciences.com, www.edgar.com and www.sedar.com.

About YM BioSciences
YM BioSciences Inc. is a drug development company primarily focused on advancing CYT387, an orally administered inhibitor of both the JAK1 and JAK2 kinases, which have been implicated in a number of hematological and immune cell disorders including myeloproliferative neoplasms and inflammatory diseases as well as certain cancers. Positive interim results have been reported from a Phase I/II trial of CYT387 in 166 patients with myelofibrosis. YM's portfolio also includes nimotuzumab, a humanized monoclonal antibody targeting EGFR with an enhanced side-effect profile over currently marketed EGFR-targeting antibodies. Nimotuzumab is being evaluated in numerous Phase II and III trials worldwide. In addition, YM has several preclinical programs underway with candidates from its library of novel compounds identified through internal research conducted at YM BioSciences Australia.

This press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risks and uncertainties that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process or the ability to obtain drug product in sufficient quantity or at standards acceptable to health regulatory authorities to complete clinical trials or to meet commercial demand; and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting. Certain of the assumptions made in preparing forward-looking statements include but are not limited to the following: that CYT387 and nimotuzumab will generate positive efficacy and safety data in ongoing and future clinical trials, and that YM as well as CIMYM's various licensees will complete their respective clinical trials and disclose data within the timelines communicated in this release. Except as required by applicable securities laws, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

YM BIOSCIENCES INC.
Condensed Consolidated Interim Statements of Financial Position
(Expressed in Canadian dollars, unless otherwise noted)
(Unaudited)

 
  September 30,   June 30,
  2012   2012 
 
Assets
 
Current assets:
  Cash and cash equivalents $ 82,612,892 $ 87,140,020
  Short-term deposits   42,933,445   45,310,288
  Accounts receivable   259,492   252,884
  Prepaid expenses   168,989   257,780
  Total current assets   125,974,818   132,960,972
 
Non-current assets:
  Property and equipment   65,387   62,118
  Intangible assets   1,502,678   2,629,682
  Total non-current assets   1,568,065   2,691,800
 
Total assets  $ 127,542,883 $ 135,652,772
 
Liabilities and Equity
 
Current liabilities:
  Accounts payable $ 1,321,253 $ 803,421
  Accrued liabilities   3,661,511   2,262,972
  Share purchase warrants   5,567,344   7,221,040
  Deferred revenue   381,270   381,270
  Total current liabilities   10,931,378   10,668,703
 
Non-current liabilities:
  Deferred revenue   1,461,535   1,556,853
  Total non-current liabilities   1,461,535   1,556,853
 
Equity
  Share capital   340,173,078   340,173,078
  Contributed surplus   16,984,637   16,712,315
  Deficit   (242,007,745)   (233,458,177)
  Total equity   115,149,970   123,427,216
 
Total liabilities and equity $ 127,542,883 $ 135,652,772

Approved by the Board and authorized for issue on November 8, 2012:

Tryon M. Williams, Director

Dr. Nick Glover, Director

YM BIOSCIENCES INC.
Condensed Consolidated Interim Statements of Loss and Comprehensive Loss
(Expressed in Canadian dollars, unless otherwise noted)
(Unaudited)

 
    Three months ended
    September  30,
    2012    2011
 
Revenue:
  Out-licensing $ 310,145 $ 250,728
 
Expenses:
  Licensing and product development   7,203,847   6,487,847
  General and administrative   2,021,699   2,160,148
    9,225,546   8,647,995
 
Loss before the undernoted   (8,915,401)   (8,397,267)
 
Finance income   1,950,215   7,502,577
Finance costs   (1,584,382)   -
 
Net loss for the period and comprehensive loss $ (8,549,568) $ (894,690)
 
Basic and diluted loss per common share $ (0.05) $ (0.01)

YM BIOSCIENCES INC.
Condensed Consolidated Interim Statements of Changes in Equity
(Expressed in Canadian dollars, unless otherwise noted)
(Unaudited)

                                 
      Share capital     Contributed            
      Number     Amount     surplus     Deficit     Total
Balance, June 30, 2012     157,546,793   $ 340,173,078   $ 16,712,315   $ (233,458,177)   $ 123,427,216
Capital transactions (note 8)                              
Net loss for the period                       (8,549,568)     (8,549,568)
                               
Transactions affecting owners of the Company, recognized directly in equity:                              
  Share-based compensation     -     -     272,322     -     272,322
  Shares issued on exercise of options     -     -     -     -     -
Total transactions affecting owners of the Company     -     -     272,322     -     272,322
                               
Balance, September 30, 2012     157,546,793   $ 340,173,078   $ 16,984,637   $ (242,007,745)   $ 115,149,970
                               
                               
                               
                               
                               
      Share capital     Contributed            
      Number     Amount     surplus     Deficit     Total
Balance, June 30, 2011     116,681,948   $ 264,548,643   $ 15,144,062   $ (213,141,438)   $ 66,551,267
Capital transactions                               
Net loss for the period     -     -     -     (894,690)     (894,690)
                               
Transactions affecting owners of the Company, recognized directly in equity:                              
  Share-based compensation     -     -     1,065,654     -     1,065,654
  Shares issued on exercise of options     29,500     38,008     (15,558)     -     22,450
Total transactions affecting owners of the Company     29,500     38,008     1,050,096     -     1,088,104
                               
Balance, September 30, 2011     116,711,448   $ 264,586,651   $ 16,194,158   $ (214,036,128)   $ 66,744,681

 



YM BIOSCIENCES INC.
Condensed Consolidated Interim Statements of Cash Flows
(Expressed in Canadian dollars, unless otherwise noted)
(Unaudited)

                 
      Three months ended
      September 30,
      2012     2011
             
Cash provided by (used in):            
             
Operating activities:            
  Net loss for the period   $ (8,549,568)   $ (894,690)
  Items not involving cash:            
    Depreciation of property and equipment     11,931     16,584
    Amortization of intangible assets     1,127,004     1,127,004
    Interest earned     (296,519)     (154,476)
    Unrealized (gain) loss on cash and cash equivalents     330,949     (1,983,577)
    Share-based compensation     272,322     1,065,654
    Change in fair value of share purchase warrants     (1,653,696)     (5,360,739)
  Changes in non-cash working capital balances:            
    Short-term deposits     (141,836)     (165,305)
    Accounts receivable     (6,608)     (61,466)
    Prepaid expenses     88,791     175,712
    Accounts payable     517,832     138,023
    Accrued liabilities      1,398,539     (88,723)
    Deferred revenue     (95,318)     (148,518)
  Net cash used in operating activities     (6,996,177)     (6,334,517)
             
Investing activities:            
  Proceeds from sale of short-term deposits     2,518,679     1,818,420
  Purchase of short-term deposits     -     (800,000)
  Interest earned     296,519     154,476
  Additions to property and equipment     (15,200)     (4,300)
  Net cash provided by investing activities     2,799,998     1,168,596
             
Financing activities:            
  Issuance of common shares on exercise of options     -     22,450
  Net cash provided by financing activities     -     22,450
             
Decrease in cash and cash equivalents     (4,196,179)     (5,143,471)
             
Impact of foreign exchange rates on cash     (330,949)     1,983,577
             
Cash and cash equivalents, beginning of period     87,140,020     32,046,630
             
Cash and cash equivalents, end of period   $ 82,612,892   $ 28,886,736

 

 

SOURCE YM BioSciences Inc.

About PR Newswire
Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest AJAXWorld RIA Stories
No matter how often you deploy your application or how sophisticated your delivery pipeline is, you always need to know the quality status of the software you are building. That can only be done if you measure it; but measure what exactly? In Part 1 we introduced the Concept of Q...
Poorly performing websites, like Twitter’s recent fiasco with Ellen’s selfie, are a constant source of irritation for users. At first you think it’s your computer, or maybe someone on your block is downloading the entire “Game of Thrones” series. But, when nothing changes after r...
Are you developing or hosting PHP applications? Are you doing performance sanity checks along your delivery pipeline? No? Not Yet? Then start with a quick check. It only takes 15 minutes and it really pays off. As a developer you can improve your code, and as somebody responsible...
Have you seen this error message before “java.sql.Exception: ORA-00060: deadlock detected while waiting for resource”? This is caused when parallel updates require locks on either rows or tables in your database. I recently ran into this exception on an instance of an IBM eComme...
When the agile movement re-cast the roles of the SDLC they did so with small projects as the baseline of their experience. A typical minimal SDLC method includes subject matter experts (those who execute the current workflow activities), a Project Manager, a Business Analyst, a S...
Subscribe to the World's Most Powerful Newsletters
Subscribe to Our Rss Feeds & Get Your SYS-CON News Live!
Click to Add our RSS Feeds to the Service of Your Choice:
Google Reader or Homepage Add to My Yahoo! Subscribe with Bloglines Subscribe in NewsGator Online
myFeedster Add to My AOL Subscribe in Rojo Add 'Hugg' to Newsburst from CNET News.com Kinja Digest View Additional SYS-CON Feeds
Publish Your Article! Please send it to editorial(at)sys-con.com!

Advertise on this site! Contact advertising(at)sys-con.com! 201 802-3021


SYS-CON Featured Whitepapers
ADS BY GOOGLE